Baseline patient characteristics.
| PsA, n = 14 | RA, n = 10 | HC, n = 16 | |
|---|---|---|---|
| Age, yrs | 48 (31–68) | 49 (26–58) | 35 (23–54) |
| Female, n (%) | 10 (71) | 8 (80) | 9 (56) |
| Symptom duration, yrs | 10 (0–24) | 7 (3–24) | – |
| BASDAI (0–100 mm VAS) | 36 (2–77) | 34 (7–71) | 2 (0–14) |
| BASFI (0–100 mm VAS) | 22 (0–54) | 15 (0–66) | 1 (0–7) |
| BASMI (0–100) | 0 (0–30) | 0 (0–0) | 0 (0–10) |
| Axial physician global assessment (0–100 mm VAS) | 25 (2–61) | 26 (6–57) | 0 (0–1) |
| Axial pain (0–100 mm VAS) | 33 (3–83) | 32 (4–76) | 0 (0–23) |
| Axial PtGA (0–100 mm VAS) | 37 (0–86) | 25 (4–76) | 0 (0–22) |
| HAQ (0–100 mm) | 0.5 (0–1.5) | 0.7 (0.3–1.8) | 0 (0–0.1) |
| Peripheral pain (0–100 mm VAS) | 31 (4–78) | 33 (0–75) | 0 (0–35) |
| Fatigue (0–100 mm VAS) | 37 (0–88) | 57 (0–78) | 4 (0–40) |
| Peripheral PtGA (0–100 mm VAS) | 47 (0–84) | 41 (0–77) | 0 (0–36) |
| No. swollen joints (0–76) | 5 (2–12) | 6 (3–15) | 0 (0–0) |
| No. tender joints (0–78) | 11 (3–24) | 8 (3–31) | 0 (0–1) |
| No. tender entheses (0–31) | 10 (0–21) | 4 (0–14) | 0 (0–3) |
| Serum CRP, mg/dL | 5 (1–13) | 5 (1–23) | 5 (1–14) |
Values are median (range). BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; BASFI: Bath Ankylosing Spondylitis Functional Index; BASMI: Bath Ankylosing Spondylitis Metrology Index; CRP: C-reactive protein; HAQ: Health Assessment Questionnaire; HC: healthy controls; PtGA: patient global assessment; PsA: psoriatic arthritis; RA: rheumatoid arthritis; VAS: visual analog scale.